Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

NCT03829657 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT03829657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
Lead sponsor
Theravance Biopharma
Phase
Phase 3
Overall status
Terminated
Start date
February 22, 2019
Completion date
November 10, 2021
Enrollment
203 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

msa, parkinson's disease (pd), pure autonomic failure (paf), symptomatic neurogenic orthostatic hypotension